Somatic mutations of the KEAP1 gene in common solid cancers

Histopathology

Volumn 60, Issue 6, 2012, Pages 943-952

  Yoo, Nam Jin ^a   Kim, Hyung Ran ^a   Kim, Yoo Ri ^a   An, Chang Hyeok ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Cancer; Cytoprotection; KEAP1; Mutation; Nuclear factor erythroid 2 related factor 2

Indexed keywords

KELCH LIKE ECH ASSOCIATED PROTEIN 1; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ARTICLE; BREAST CANCER; COLON CANCER; COLORECTAL CANCER; DNA SEQUENCE; GENE LOCUS; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LIVER CELL CARCINOMA; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SOLID TUMOR; SOMATIC MUTATION; STOMACH CANCER;

DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; MALE; MUTATION; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84862786878     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04178.x     Document Type: Article

References (27)

1. Kasai H, Kawai K. Oxidative DNA damages: mechanisms and significance in health and disease. Antioxid. Redox Signal. 2006; 8; 981-983.
2. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free Radic. Biol. Med. 2009; 47; 1304-1309.
3. Banning A, Deubel S, Kluth D et al. The GI-GPx gene is a target for Nrf2. Mol. Cell. Biol. 2005; 25; 4914-4923.
4. Ishii T, Itoh K, Takahashi S et al. Transcription factor Nrf2 coordinately regulates a group of oxidative stress-inducible genes in macrophages. J. Biol. Chem. 2000; 275; 16023-16029.
5. Katoh Y, Itoh K, Yoshida E et al. Two domains of Nrf2 cooperatively bind CBP, a CREB binding protein, and synergistically activate transcription. Genes Cells 2001; 6; 857-868.
6. Kim YC, Masutani H, Yamaguchi Y et al. Hemin-induced activation of the thioredoxin gene by Nrf2. A differential regulation of the antioxidant responsive element by a switch of its binding factors. J. Biol. Chem. 2001; 276; 18399-18406.
7. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab. Rev. 2006; 38; 769-789.
8. Kobayashi A, Kang MI, Okawa H et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol. Cell. Biol. 2004; 24; 7130-7139.
9. Kobayashi A, Kang MI, Watai Y et al. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. Mol. Cell. Biol. 2006; 26; 221-229.
10. Zhang DD, Lo SC, Cross JV et al. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol. Cell. Biol. 2004; 24; 10941-10953.
11. Moi P, Chan K, Asunis I et al. Isolation of NF-E2-related factor 2 (Nrf2), a NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 repeat of the beta-globin locus control region. Proc. Natl Acad. Sci. USA 1994; 91; 9926-9930.
12. Lau A, Villeneuve NF, Sun Z et al. Dual roles of Nrf2 in cancer. Pharmacol. Res. 2008; 58; 262-270.
13. Shibata T, Ohta T, Tong KI et al. Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy. Proc. Natl Acad. Sci. USA 2008; 105; 13568-13573.
14. Padmanabhan B, Tong KI, Ohta T et al. Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer. Mol. Cell 2006; 21; 689-700.
15. Kim YR, Oh JE, Kim MS et al. Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin. J. Pathol. 2010; 220; 446-451.
16. Singh A, Misra V, Thimmulappa RK et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3; e420.
17. Shibata T, Kokubu A, Gotoh M et al. Genetic alteration of Keap1 confers constitutive Nrf2 activation and resistance to chemotherapy in gallbladder cancer. Gastroenterology 2008; 135; 1358-1368.
18. Takahashi T, Sonobe M, Menju T et al. Mutations in Keap1 are a potential prognostic factor in resected non-small cell lung cancer. J. Surg. Oncol. 2010; 101; 500-506.
19. Sjöblom T, Jones S, Wood LD et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006; 314; 268-274.
20. Lee SH, Shin MS, Park WS et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer. Oncogene 1999; 18; 3754-3760.
21. Lee JW, Soung YH, Kim SY et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas. Oncogene 2005; 24; 1477-1480.
22. Wakabayashi N, Itoh K, Wakabayashi J et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat. Genet. 2003; 35; 238-245.
23. Ohta T, Iijima K, Miyamoto M et al. Loss of Keap1 function activates Nrf2 and provides advantages for lung cancer cell growth. Cancer Res. 2008; 68; 1303-1309.
24. Tong KI, Katoh Y, Kusunoki H et al. Keap1 recruits Neh2 through binding to ETGE and DLG motifs: characterization of the two-site molecular recognition model. Mol. Cell. Biol. 2006; 26; 2887-2900.
25. McMahon M, Thomas N, Itoh K et al. Dimerization of substrate adaptors can facilitate cullin-mediated ubiquitylation of proteins by a 'tethering' mechanism: a two-site interaction model for the Nrf2-Keap1 complex. J. Biol. Chem. 2006; 281; 24756-24768.
26. Wakabayashi N, Dinkova-Kostova AT, Holtzclaw WD et al. Protection against electrophile and oxidant stress by induction of the phase 2 response: fate of cysteines of the Keap1 sensor modified by inducers. Proc. Natl Acad. Sci. USA 2002; 99; 7610-7615.
27. Nioi P, Nguyen T. A mutation of Keap1 found in breast cancer impairs its ability to repress Nrf2 activity. Biochem. Biophys. Res. Commun. 2007; 362; 816-821.